Fisher Asset Management LLC Sells 34,185 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Posted by Defense World Staff on Apr 25th, 2023

Fisher Asset Management LLC reduced its position in Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) by 8.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 355,613 shares of the medical equipment provider’s stock after selling 34,185 shares during the quarter. Fisher Asset Management LLC owned approximately 0.52% of Lantheus worth $18,122,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of LNTH. BlackRock Inc. lifted its position in shares of Lantheus by 0.8% during the 3rd quarter. BlackRock Inc. now owns 10,831,691 shares of the medical equipment provider’s stock valued at $761,795,000 after acquiring an additional 90,399 shares during the period. Vanguard Group Inc. grew its stake in shares of Lantheus by 4.4% in the 3rd quarter. Vanguard Group Inc. now owns 7,765,120 shares of the medical equipment provider’s stock worth $546,121,000 after acquiring an additional 326,396 shares in the last quarter. Alliancebernstein L.P. grew its stake in shares of Lantheus by 2,826.5% in the 3rd quarter. Alliancebernstein L.P. now owns 2,704,099 shares of the medical equipment provider’s stock worth $190,179,000 after acquiring an additional 2,611,699 shares in the last quarter. State Street Corp grew its stake in shares of Lantheus by 0.3% in the 2nd quarter. State Street Corp now owns 2,393,559 shares of the medical equipment provider’s stock worth $158,047,000 after acquiring an additional 7,307 shares in the last quarter. Finally, Lord Abbett & CO. LLC grew its position in Lantheus by 33.9% during the third quarter. Lord Abbett & CO. LLC now owns 1,908,416 shares of the medical equipment provider’s stock valued at $134,219,000 after buying an additional 483,276 shares during the period. 97.62% of the stock is owned by institutional investors.

Lantheus Stock Performance

NASDAQ:LNTH opened at $91.22 on Tuesday. The stock has a market cap of $6.16 billion, a P/E ratio of 268.29 and a beta of 0.66. The firm’s fifty day simple moving average is $77.15 and its 200 day simple moving average is $65.11. Lantheus Holdings, Inc. has a twelve month low of $47.46 and a twelve month high of $91.62. The company has a quick ratio of 2.59, a current ratio of 2.74 and a debt-to-equity ratio of 1.25.

Lantheus (NASDAQ:LNTH – Get Rating) last announced its quarterly earnings data on Thursday, February 23rd. The medical equipment provider reported $1.28 EPS for the quarter, beating the consensus estimate of $0.87 by $0.41. The business had revenue of $263.17 million during the quarter, compared to analyst estimates of $244.61 million. Lantheus had a return on equity of 51.60% and a net margin of 3.00%. As a group, research analysts predict that Lantheus Holdings, Inc. will post 4.46 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Truist Financial increased their price target on shares of Lantheus from $94.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, April 12th. Mizuho increased their price target on shares of Lantheus from $105.00 to $115.00 and gave the stock a “buy” rating in a report on Friday, February 24th. JMP Securities initiated coverage on shares of Lantheus in a research note on Wednesday, March 8th. They issued an “outperform” rating and a $120.00 target price on the stock. Finally, StockNews.com initiated coverage on shares of Lantheus in a research note on Thursday, March 16th. They set a “hold” rating on the stock. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $110.83.

Insider Buying and Selling at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 7,705 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $72.56, for a total transaction of $559,074.80. Following the completion of the transaction, the chief accounting officer now owns 63,626 shares of the company’s stock, valued at $4,616,702.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Robert J. Jr. Marshall sold 5,000 shares of Lantheus stock in a transaction dated Wednesday, March 15th. The stock was sold at an average price of $71.58, for a total value of $357,900.00. Following the completion of the transaction, the chief financial officer now owns 128,298 shares of the company’s stock, valued at approximately $9,183,570.84. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Andrea Sabens sold 7,705 shares of Lantheus stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $72.56, for a total value of $559,074.80. Following the completion of the transaction, the chief accounting officer now directly owns 63,626 shares of the company’s stock, valued at approximately $4,616,702.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 235,905 shares of company stock valued at $17,856,980. 1.50% of the stock is currently owned by company insiders.

Lantheus Profile

(Get Rating)

Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.